Since the introduction of the low dose biosyn selenium product in mid-1980, trademarked selenase®, there have been major developments in the clinical usage of selenium for various disease indications other than in cancer. As new information became available, it pointed to selenium deficiency in sepsis, heart surgery, intensive care patients, organ transplantation, plastic surgery, resusitation, vascular surgery, HIV/AIDS, cystic fibrosis, and cardiomyopathy.